SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer

被引：5
|
作者：
Westin, Shannon [1 ]
Kurnit, Katherine [2 ]
Fellman, Bryan [1 ]
Bhosale, Priya [1 ]
Hong, David [1 ]
Karp, Daniel [1 ]
Naing, Aung [1 ]
Pant, Shubham [1 ]
Piha-Paul, Sarina [1 ]
Fu, Siqing [1 ]
Rodon, Jordi [1 ]
Yap, Timothy [1 ]
Dumbrava, Ecaterina [1 ]
Sood, Anil [1 ]
Shafer, Aaron [1 ]
Soliman, Pamela [1 ]
Gershenson, David [1 ]
Kabil, Nashwa [3 ]
Coleman, Robert [4 ]
Mills, Gordon [5 ]
Meric-Bernstam, Funda [1 ]
机构：
[1] UT MD Anderson Canc Ctr Houston, Houston, TX USA
[2] Univ Chicago, Coll Med, Chicago, IL USA
[3] AstraZeneca, Gaithersburg, MD USA
[4] US Oncol Res, The Woodlands, TX USA
[5] OHSU, Portland, OR USA
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA 9
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [41] Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge
    Shih, Chi-Ting
    Huang, Tzu-Ting
    Nair, Jayakumar R.
    Ibanez, Kristen R.
    Lee, Jung-Min
    CELLS, 2024, 13 (22)
  • [42] Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
    Kummar, Shivaani
    Chen, Alice
    Ji, Jiuping
    Zhang, Yiping
    Reid, Joel M.
    Ames, Matthew
    Jia, Lee
    Weil, Marcie
    Speranza, Giovanna
    Murgo, Anthony J.
    Kinders, Robert
    Wang, Lihua
    Parchment, Ralph E.
    Carter, John
    Stotler, Howard
    Rubinstein, Larry
    Hollingshead, Melinda
    Melillo, Giovanni
    Pommier, Yves
    Bonner, William
    Tomaszewski, Joseph E.
    Doroshow, James H.
    CANCER RESEARCH, 2011, 71 (17) : 5626 - 5634
  • [43] Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
    Konstantinopoulos, Panagiotis A.
    Barry, William T.
    Birrer, Michael
    Westin, Shannon N.
    Farooq, Sarah
    Cadoo, Karen
    Whalen, Christin
    Luo, Weixiu
    Liu, Hui
    Aghajanian, Carol
    Solit, David B.
    Mills, Gordon B.
    Taylor, Barry S.
    Won, Helen
    Berger, Michael F.
    Palakurthi, Sangeetha
    Liu, Joyce F.
    Cantley, Lew
    Kaufmann, Scott H.
    Swisher, Elizabeth M.
    D'Andrea, Alan D.
    Winer, Eric
    Wulf, Gerburg M.
    Matulonis, Ursula A.
    CANCER RESEARCH, 2017, 77
  • [44] Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer
    Qin Tang
    Xin Wang
    Haixia Wang
    Lin Zhong
    Dongling Zou
    Cancer Biology & Medicine, 2023, 20 (12) : 915 - 921
  • [45] Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer
    Tang, Qin
    Wang, Xin
    Wang, Haixia
    Zhong, Lin
    Zou, Dongling
    CANCER BIOLOGY & MEDICINE, 2023, 20 (12)
  • [46] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    Grilley-Olson, J. E.
    Bedard, P. L.
    Fasolo, A.
    Cornfeld, M.
    Cartee, L.
    Razak, A. R. Abdul
    Stayner, L. -A.
    Wu, Y.
    Greenwood, R.
    Singh, R.
    Lee, C. B.
    Bendell, J.
    Burris, H. A.
    Del Conte, G.
    Sessa, C.
    Infante, J. R.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (06) : 740 - 749
  • [47] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    J. E. Grilley-Olson
    P. L. Bedard
    A. Fasolo
    M. Cornfeld
    L. Cartee
    A. R. Abdul Razak
    L.-A. Stayner
    Y. Wu
    R. Greenwood
    R. Singh
    C. B. Lee
    J. Bendell
    H. A. Burris
    G. Del Conte
    C. Sessa
    J. R. Infante
    Investigational New Drugs, 2016, 34 : 740 - 749
  • [48] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)
    Simpkins, Fiona
    Nasioudis, Dimitrios
    Wethington, Stephanie L.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Torigian, Drew A.
    Omran, Dalia K.
    Rodriguez, Diego
    Smith, Simon
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei-Ting
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Giuntoli, Robert Lawrence, II
    Liu, Joyce F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Weekes, Colin
    Lockhart, Albert
    LoRusso, Patricia
    Murray, Elaine
    Park, Erica
    Tagen, Mike
    Singh, Jatinder
    Sarkar, Indrani
    Mueller, Lars
    Dokainish, Hatem
    Shapiro, Geoffrey
    Burris, Howard
    ONCOLOGIST, 2020, 25 (10): : 833 - +
  • [50] Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No
    Saad, Fred
    EUROPEAN UROLOGY FOCUS, 2024, 10 (04): : 506 - 508
12345